STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients

Status:
Terminated

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Treatment of anemia associated with chronic kidney disease (CKD) during 36 weeks with safety follow up phase of 52 weeks

Phase 3

Amgen

Darbepoetin alfa